The acute hepatic porphyrias (AHP) are rare disorders that typically become apparent during adulthood and may have varied presentations. Most of these quiz questions are derived from recent ...

is now funded across Canada through both public and private insurance plans for patients living with acute hepatic porphyria (AHP), including those diagnosed with acute intermittent porphyria (AIP ...

Because acute attacks of porphyria may be precipitated by anticonvulsants, a therapeutic dilemma arises when seizures complicate hepatic porphyria. The list of unsafe agents includes barbiturates ...

In 2019, the FDA approved Givlaari for acute hepatic porphyria. In 2020, the FDA approved Oxlumo injection for subcutaneous ...

Givlaari is approved for the treatment of acute hepatic porphyria. Oxlumo is approved for treating primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

SG Americas Securities LLC cut its position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) by 50.8% ...